Digipath, Inc.: management transactions · United States · SEC (Form 4)

About Digipath, Inc.

Digipath, Inc. (ticker: DIGP) is a United States-based company whose shares have traded in the U.S. public markets, historically outside the main NYSE/NASDAQ large-cap universe and more in the realm of microcap/over-the-counter equities. The company was incorporated in Nevada in 2010 and is headquartered in Las Vegas, Nevada, United States. For investors, the key point is that Digipath should be viewed as a very small, special-situation healthcare name with a long history in digital pathology and laboratory-related services, but with a much narrower operating footprint today than in its earlier years. The company originally built its business around digital pathology solutions and advisory services for healthcare clients. In practical terms, that meant offering technology-enabled pathology workflows and related consulting across the chain of clinical operations, commercial outreach, product development, regulatory support, and customer service. Earlier SEC disclosures also show an emphasis on serving manufacturers, laboratories, pathology practices, and centers of excellence. Over time, Digipath operated through a small group of subsidiaries and attempted to expand into adjacent healthcare and laboratory activities. Its customer base has been described as being substantially within the United States, which reinforces the domestic nature of the business. More recently, however, the company has undergone a major corporate simplification. SEC filings indicate that on February 20, 2024, Digipath completed the sale of the net assets of its Digipath Labs subsidiary, and that a final working-capital adjustment was settled in June 2024. The transaction produced a gain on sale, but it also marked a clear reduction in the company’s operating scope. As a result, Digipath no longer looks like a conventional operating laboratory platform; instead, it appears to be a smaller residual corporate entity with a reduced asset base and a business model that may depend on strategic redeployment, cost control, and balance-sheet management. From a competitive standpoint, Digipath is not positioned alongside the large, diversified diagnostic leaders or major health-tech platforms. It occupies a niche and increasingly constrained position in digital pathology and related healthcare services. That makes the name highly event-driven and sensitive to corporate actions, SEC disclosures, and insider transaction activity reported on Form 4. Geographically, the business remains U.S.-centric, with headquarters in Las Vegas and limited evidence of meaningful international operating scale. For French, Belgian, and Swiss investors, DIGP is best understood as a speculative U.S. healthcare microcap rather than a mature, scaled healthcare services company on the NYSE or NASDAQ.